Phase II study to evaluate the efficacy and safety of ALX-0061, administered
subcutaneously, in patients with moderate to severe, active systemic lupus
erythematosus (SLE)
GHENT, Belgium, 4 August 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today a ...
↧